NextMR Spine
MRI2CT, Inc. · Decision date Sep 4, 2026
What did the FDA decide?
MRI2CT, Inc. received a substantially equivalent (SESE) decision for NextMR Spine on September 4, 2026, under 510(k) number K260525. The submission was received February 17, 2026, and reviewed in the Radiology panel under 21 CFR 892.2050, product code QIH, Class II. The device is described as software-only, cloud-based MRI image enhancement that generates DICOM series for visualizing spinal bony anatomy in the lumbar vertebrae (L1–L5) and sacrum in patients 18 and older.
The listed predicate is BoneMRI (MRIguidance B.V., K233030), also product code QIH. The summary characterizes NextMR Spine's anatomical scope as narrower and its age range as more conservative than the predicate, and states the device is not intended to replace CT in general or for tumor diagnosis or monitoring. SESE denotes 510(k) clearance, not PMA approval. The summary's performance claims are not independently verified here, and the reviewed clinical evidence and numerical results are not available in the provided excerpts.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260525
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- MRI2CT, Inc.
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- MRI2CT, Inc.
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K260525 received
Application receipt date recorded by FDA.
K260525 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
MRI2CT, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Claymont, DE
Sources and methodology
- Original FDA record: K260525
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


